We are committed to utilizing the immune system to prevent and fight disease.
Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceutical company with multiple product candidates in development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. We develop immunotherapies based on cutting-edge Toll-Like Receptor (TLR) biology and its ability to modulate the immune system.
HBsAg-1018 (HEPLISAV-B™) - Hepatitis B Vaccine
HBsAg-1018 is an adult hepatitis B vaccine in Phase 3 development that utilizes a proprietary TLR9 agonist to elicit a focused immune response designed to provide protection against hepatitis B. We have submitted the Biologics License Application to the U.S. Food and Drug Administration (FDA). The FDA has established August 10, 2017 as the Prescription Drug User Fee Act action date.
SD-101 - Cancer Immunotherapy
We are utilizing our expertise in TLR biology to develop treatments for cancer by focusing the power of the body’s immune response on cancer cells through optimal stimulation of TLR9 signaling. Our lead cancer immunotherapy compound, SD-101, is a TLR9 agonist designed specifically for cancer and capable of maximal type 1 IFN induction and efficient maturation of plasmacytoid dendritic cells (PDC) to antigen-presenting cells. Our approach provides multiple mechanisms for attacking the tumors along with developing immune memory associated with antigens found in the tumor.
TLR signaling plays an important role in a variety of immune-mediated diseases including asthma and certain autoimmune and inflammatory diseases. Through modulation of TLR signaling we are developing compounds to inhibit stimulation of TLRs that lead to autoimmune and inflammatory diseases as well using TLR agonist to rebalance the Th1 versus Th2 response in asthma.